Anti-TNFSF11 (Denosumab), Human IgG2 Antibody

Anti-TNFSF11 (Denosumab), Human IgG2 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a fully human IgG2 monoclonal antibody that specifically targets receptor activator of nuclear factor kappa-B ligand (RANKL), a protein that plays a key role in the formation, function, and survival of osteoclasts. RANKL belongs to the TNF superfamily of ligands. Interaction with the receptor (RANK) expressed on pre-osteoclast and mature osteoclast cells results in the activation, migration, differentiation, and fusion of hematopoietic cells of osteoclast lineage, and promotes bone resorption. By preventing the RANKL-RANK interaction, the antibody inhibits bone resorption and increases bone mass density and strength, thus decreasing the risk of hip, vertebral, and non-vertebral fractures. The original monoclonal antibody received approval from the FDA for the treatment of osteoporosis in postmenopausal women, and to treat patients with bone metastases

Immunogen Sequence:Human TNFSF11

Target Alternative Name:CD254, ODF, OPGL, sOdf, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2

Species Reactivities:Human

Tag Line:The biosimilar is a human monoclonal antibody that targets RANKL and inhibits the binding to its receptor RANK, thus reducing bone resorption and increasing bone mass and strength.

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.